Items where authors include "Kanthou, C."

Article

Joussaume, A. orcid.org/0009-0009-0457-1437, Kanthou, C. orcid.org/0000-0002-5643-4743, Pardo, O.E. et al. (3 more authors) (2024) The vitamin K-dependent anticoagulant factor, protein S, regulates vascular permeability. Current Issues in Molecular Biology, 46 (4). pp. 3278-3293. ISSN 1466-531X

Psoma, S.D. orcid.org/0000-0002-9375-8173 and Kanthou, C. (2023) Wearable insulin biosensors for diabetes management: advances and challenges. Biosensors, 13 (7). 719. ISSN 2079-6374

Holmes, T., Brown, A.W., Suggitt, M. et al. (5 more authors) (2020) The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. Scientific Reports, 10 (1). 9926. ISSN 2045-2322

Dardente, H., English, W.R. orcid.org/0000-0003-3024-2441, Valluru, M.K. et al. (2 more authors) (2020) Debunking the myth of the endogenous antiangiogenic Vegfaxxxb transcripts. Trends in Endocrinology & Metabolism, 31 (6). pp. 398-409. ISSN 1043-2760

Brown, A.W., Holmes, T., Fisher, M. et al. (3 more authors) (2018) Cover feature : Evaluation of sydnone-based analogues of Combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy (ChemMedChem 24/2018). ChemMedChem, 13 (24). p. 2600. ISSN 1860-7179

Harrity, J.P.A., Brown, A., Holmes, T. et al. (3 more authors) (2018) Evaluation of sydnone-based analogs of combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy. ChemMedChem, 13 (24). pp. 2618-2626. ISSN 1860-7179

Shepherd, J. orcid.org/0000-0001-7661-0698, Fisher, M., Welford, A. et al. (3 more authors) (2017) The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget, 2017 (8). pp. 95648-95661. ISSN 1949-2553

English, W.R. orcid.org/0000-0003-3024-2441, Lunt, S.J., Fisher, M. et al. (8 more authors) (2017) Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma. Cancer Research, 77 (10). pp. 2633-2646. ISSN 0008-5472

Brown, A.W., Fisher, M., Tozer, G.M. et al. (2 more authors) (2016) Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. Journal of Medicinal Chemistry, 59 (20). pp. 9473-9488. ISSN 0022-2623

Williams, L. J., Mukherjee, D., Fisher, M. et al. (4 more authors) (2014) An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. British Journal of Pharmacology, 171 (21). pp. 4902-4913. ISSN 0007-1188

Kanthou, C., Dachs, G.U., Lefley, D.V. et al. (8 more authors) (2014) Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics. PLoS ONE, 9 (8). e104015. ISSN 1932-6203

Harris, S., Craze, M., Newton, J. et al. (4 more authors) (2012) Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale. PLoS ONE, 7 (5). ARTN e35231. ISSN 1932-6203

Reyes-Aldasoro, C.C., Williams, L.J., Akerman, S. et al. (2 more authors) (2011) An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections. Journal of Microscopy, 242 (3). pp. 262-278. ISSN 0022-2720

Dachs, G.U., Steele, A.J., Coralli, C. et al. (7 more authors) (2006) Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. BMC Cancer, 6 (Art. N). ISSN 1471-2407

Monograph

Kanthou, C. (2011) Drug Report: lexibulin (iv infusion, cancer), YM BioSciences. Report. Drug Report . Thomson Reuters

McMillan, T.J., Bennett, M.R., Bridges, B.A. et al. (11 more authors) (2010) 'Circulatory Disease Risk', report of the independent Advisory Group on Ionising Radiation. Research Report. Documents of the Health Protection Agency (RCE-16). Health Protection Agency , London, UK. ISSN 978-0-85951-676-1